FDA Panel Favors Nixing Avastin For Breast Cancer

Law360, New York (July 21, 2010, 7:17 PM EDT) -- A U.S. Food and Drug Administration advisory committee has recommended revoking approval of Genentech Inc.'s blockbuster cancer drug Avastin for use in breast cancer patients, saying the product may not help patients and could worsen the side effects of chemotherapy.

At a meeting held Tuesday in Gaithersburg, Md., the FDA's 13-member Oncologic Drugs Advisory Committee voted 12-1 to revoke Avastin for breast cancer, but did not address other types of cancer for which the drug has been approved, an FDA spokeswoman confirmed Wednesday night.

If the...
To view the full article, register now.